This site is intended for healthcare professionals

Merck Inc., and Ridgeback Bio collaborate to advance development of novel antiviral candidate, EIDD-2801 to treat COVID-19 .

Read time: 1 mins
Last updated:29th May 2020
Published:28th May 2020
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest